To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Clinical Laboratory Tests Market size was valued at USD 94.76 Billion in 2021 and is poised to grow from USD 103.67 billion in 2022 to USD 212.71 billion by 2030, growing at a CAGR of 9.4% during the forecast period (2023-2030).

The major players in the clinical laboratory test industry are continually working to improve patient outcomes and the effectiveness and effectiveness of healthcare by introducing new technologies and altering those that already exist. For instance, Omega Laboratories will begin conducting urine tests as part of its new Urine Drugs of Use Testing Services in December 2022, complementing its DNA testing in Canada. 'Quest Diagnostics Incorporated', 'Laboratory Corporation of America Holdings (LabCorp)', 'Siemens Healthineers AG', 'Roche Diagnostics', 'Abbott Laboratories', 'Thermo Fisher Scientific Inc.', 'Bio-Rad Laboratories, Inc.', 'Danaher Corporation', 'Sysmex Corporation', 'Becton, Dickinson and Company (BD)', 'bioMérieux SA', 'Agilent Technologies, Inc.', 'Genomic Health, Inc.', 'Myriad Genetics, Inc.', 'Cepheid (a subsidiary of Danaher Corporation)', 'QIAGEN N.V.', 'Hologic, Inc.', 'Ortho Clinical Diagnostics', 'PerkinElmer, Inc.', 'GenMark Diagnostics, Inc.'

The growing prevalence of chronic diseases and infectious diseases worldwide is driving the demand for clinical laboratory tests. These tests play a crucial role in disease diagnosis, monitoring, and treatment.

Increasing Demand for Molecular Diagnostics: There is a growing demand for molecular diagnostic tests that can detect genetic variations, infectious diseases, and other biomarkers at the molecular level. Advances in genomics and targeted therapies have led to the integration of molecular diagnostics into routine clinical practice.

North America dominated the market in terms of share in 2022, and it is anticipated that it will continue to do so during the forecast period. This might be linked to the region's growing senior population, increased chronic illness prevalence, including cancer, and strong market penetration of cutting-edge diagnostic techniques. One of the primary cause’s deaths in North America, reported to the American Cancer Society as a whole, is cancer. Prostate cancer in males and cancer of the breast in women are the two cancers that are most frequently diagnosed. The regional market is anticipated to be driven by factors like rising patient awareness and growing inclination for novel techniques.

Feedback From Our Clients

Global Clinical Laboratory Tests Market

Product ID: SQMIG35I2276